



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider the use of patient-activated or autoactivated external ambulatory event monitors (AEMs) OR continuous ambulatory monitors that record and store information for periods longer than 48 hours as a diagnostic alternative to Holter monitoring in the following situations to be **eligible for coverage:****

Patient Selection Criteria

Coverage eligibility will be considered when any of the following is met:

- Patients who experience infrequent symptoms (less frequently than every 48 hours) suggestive of cardiac arrhythmias (ie, palpitations, dizziness, presyncope, or syncope); or
- Patients with atrial fibrillation (AF) who have been treated with catheter ablation, and in whom discontinuation of systemic anticoagulation is being considered; or
- Patients with cryptogenic stroke who have a negative standard workup for AF including a 24-hour Holter monitor (see Policy Guidelines section).

Based on review of available data, the Company may consider the use of implantable AEMs, either patient-activated or autoactivated, may be considered **eligible for coverage**** in the following situations:

- In the small subset of patients who experience recurrent symptoms (i.e. palpitations, dizziness, presyncope, or syncope) so infrequently (i.e. less than once every 2 weeks) that a prior trial of other external AEMs has been unsuccessful; or

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

- In patients who require long-term monitoring for AF or possible AF, i.e., after AF ablation, in patients with cryptogenic stroke and negative standard workup for AF including a 24-hour Holter (see Policy Guidelines section).

Based on review of available data, the Company may consider the use of outpatient cardiac telemetry (also known as mobile cardiac outpatient telemetry) in patients with cryptogenic stroke or transient ischemic attack, who have a negative standard workup for atrial fibrillation including a 24-hour Holter monitor or 48-hour telemetry (see Policy Guidelines section), to be **eligible for coverage**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers other uses of AEMs, including outpatient cardiac telemetry and mobile applications, including but not limited to monitoring asymptomatic patients with risk factors for arrhythmia, monitoring the effectiveness of antiarrhythmic medications, and detection of myocardial ischemia by detecting ST-segment changes to be **investigational**.*

The use of outpatient cardiac telemetry when patient selection criteria are not met is considered to be **investigational**.*

Policy Guidelines

The available evidence has suggested that long-term monitoring for atrial fibrillation post ablation or after cryptogenic stroke is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not well-defined. Trials demonstrating improved outcomes have used either event monitors or implantable monitors. In addition, there are individual patient considerations that may make 1 type of monitor preferable over another.

Therefore, for the evaluation of patients with cryptogenic stroke who have had a negative standard workup for atrial fibrillation including 24-hour Holter monitoring, or for the evaluation of atrial fibrillation after an ablation procedure, the use of long-term monitoring with an external event monitor, OR a continuous ambulatory monitor that records and stores information for periods longer

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

than 48 hours, OR an implantable ambulatory monitor may be considered medically necessary for patients who meet the criteria outlined above.

The Holter monitor is recommended if transient loss of consciousness occurs several times a week. If the frequency of transient loss of consciousness is every one to two weeks, an external event recorder is recommended; and if the frequency is less than once every two weeks, an implantable event recorder is recommended.

Examples of devices:

- Autotriggered or patient-triggered: Reveal[®] XT ICM (Medtronic) and Confirm Rx Insertable[™] Cardiac Monitor (Abbott)
- Autotriggered: BioMonitor, Biotronik)

This section discusses the use of ILR, with a focus on clinical situations when use of an ILR at the beginning of a diagnostic pathway is indicated. It is expected that a longer period of monitoring with any device category is associated with a higher diagnostic yield. A progression in diagnostics, from an external event monitor to ILR, in cases where longer monitoring is needed is considered appropriate. However, there may be situations where it is sufficiently likely that long-term monitoring will be needed and that an ILR as an initial strategy may be reasonable.

The purpose of ILRs in patients with signs or symptoms suggestive of arrhythmia with infrequent symptoms is to provide an alternative method of arrhythmia detection.

ILRs store electrical cardiac activity data. When activated (by patient or automatically), the cardiac activity is recorded from the memory loop. ILRs are implanted under the skin in the precordial area. Several RCTs have reported high rates of arrhythmia detection with the use of ILRs compared with external event monitoring or Holter monitoring. These studies support the use of a progression in diagnostics from an external event monitor to ILR when longer monitoring is needed. Some available trials evaluating the detection of AF after ablation procedures or in patients with cryptogenic stroke used ILRs as an initial ambulatory monitoring strategy, after a negative Holter monitor. Many observational studies reported the initiation of treatment (for example, anticoagulation therapy or pacemaker implantation) following the confirmation of diagnoses with the ILR. Because these treatments are known to be effective, it can be concluded that long-term monitoring with ILRs will improve health outcomes.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Background/Overview

Cardiac Arrhythmias

Cardiac monitoring is routinely used in the inpatient setting to detect acute changes in heart rate or rhythm that may need urgent response. For some conditions, a more prolonged period of monitoring in the ambulatory setting is needed to detect heart rate or rhythm abnormalities that may occur infrequently. These cases may include the diagnosis of arrhythmias in patients with signs and symptoms suggestive of arrhythmias as well as the evaluation of paroxysmal AF.

Cardiac arrhythmias may be suspected because of symptoms suggestive of arrhythmias, including palpitations, dizziness, or syncope or presyncope, or because of abnormal heart rate or rhythm noted on exam. A full discussion of the differential diagnosis and evaluation of each of these symptoms is beyond the scope of this review, but some general principles on the use of ambulatory monitoring are discussed.

Arrhythmias are an important potential cause of syncope or near syncope, which in some cases may be described as dizziness. An electrocardiogram (ECG) is generally indicated whenever there is suspicion of a cardiac cause of syncope. Some arrhythmic causes will be apparent on ECG. However, for patients in whom an ECG is not diagnostic, longer monitoring may be indicated. The 2009 joint guidelines from the European Society of Cardiology and 3 other medical specialty societies suggested that, in individuals with clinical or ECG features suggesting an arrhythmic syncope, ECG monitoring is indicated; the guidelines also stated that the "duration (and technology) of monitoring should be selected according to the risk and the predicted recurrence rate of syncope." Similarly, guidelines from the National Institute for Health and Care Excellence (2014) on the evaluation of transient loss of consciousness, have recommended the use of an ambulatory ECG in individuals with a suspected arrhythmic cause of syncope. The type and duration of monitoring recommended is based on the individual's history, particularly the frequency of transient loss of consciousness. The Holter monitor is recommended if transient loss of consciousness occurs several times a week. If the frequency of transient loss of consciousness is every one to two weeks, an external event recorder is recommended; and if the frequency is less than once every two weeks, an implantable event recorder is recommended.

Similar to syncope, the evaluation and management of palpitations is patient-specific. In cases where the initial history, examination, and ECG findings are suggestive of an arrhythmia, some form of

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

ambulatory ECG monitoring is indicated. A position paper from the European Heart Rhythm Association (2011) indicated that, for individuals with palpitations of unknown origin who have clinical features suggestive of arrhythmia, referral for specialized evaluation with consideration for ambulatory ECG monitoring is indicated.

Atrial Fibrillation Detection

AF is the most common arrhythmia in adults. It may be asymptomatic or be associated with a broad range of symptoms, including lightheadedness, palpitations, dyspnea, and a variety of more nonspecific symptoms (eg, fatigue, malaise). It is classified as paroxysmal, persistent, or permanent based on symptom duration. Diagnosed AF may be treated with antiarrhythmic medications with the goal of rate or rhythm control. Other treatments include direct cardioversion, catheter-based radiofrequency- or cryo-energy-based ablation, or one of several surgical techniques, depending on the patient's comorbidities and associated symptoms.

Stroke in AF occurs primarily as a result of thromboembolism from the left atrium. The lack of atrial contractions in AF leads to blood stasis in the left atrium, and this low flow state increases the risk of thrombosis. The area of the left atrium with the lowest blood flow in AF, and therefore the highest risk of thrombosis, is the left atrial appendage. Multiple clinical trials have demonstrated that anticoagulation reduces the ischemic stroke risk in patients at moderate- or high-risk of thromboembolic events. Oral anticoagulation in patients with AF reduces the risk of subsequent stroke and was recommended by American Heart Association, American College of Cardiology, and Heart Rhythm Society (2014) joint guidelines on patients with a history of stroke or transient ischemic attack.

Ambulatory ECG monitoring may play a role in several situations in the detection of AF. In patients who have undergone ablative treatment for AF, if ongoing AF can be excluded with reasonable certainty, including paroxysmal AF which may not be apparent on ECG during an office visit, anticoagulation therapy could potentially be stopped. In some cases where identifying paroxysmal AF is associated with potential changes in management, longer term monitoring may be considered. There are well-defined management changes that occur in patients with AF. However, until relatively recent the specific role of long-term (ie, >48 hours) monitoring in AF was not well-described.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Patients with cryptogenic stroke are often monitored for the presence of AF because AF is estimated to be the cause of cryptogenic stroke in more than 10% of patients, and AF increases the risk of stroke. Paroxysmal AF confers an elevated risk of stroke, just as persistent and permanent AF do. In individuals with a high-risk of stroke, particularly those with a history of ischemic stroke that is unexplained by other causes, prolonged monitoring to identify paroxysmal AF has been investigated.

Cardiac Rhythm Ambulatory Monitoring Devices

Ambulatory cardiac monitoring with a variety of devices permits the evaluation of cardiac electrical activity over time, in contrast to a static ECG, which only permits the detection of abnormalities in cardiac electrical activity at a single point in time.

A Holter monitor is worn continuously and records cardiac electrical output continuously throughout the recording period. Holter monitors are capable of recording activity for 24 to 72 hours. Traditionally, most Holter monitors have three channels based on three ECG leads. However, some currently available Holter monitors have up to 12 channels. Holter monitors are an accepted intervention in a variety of settings where a short period (24-48 hours) of comprehensive cardiac rhythm assessment is needed (eg, suspected arrhythmias when symptoms [syncope, palpitations] are occurring daily). These devices are not the focus of this review.

Various classes of devices are available for situations where longer monitoring than can be obtained with a traditional Holter monitor is needed. Because there may be many devices within each category, a comprehensive description of each is beyond our scope. Devices vary in how data are transmitted to the location where the ECG output is interpreted. Data may be transmitted via cellular phone or landline, or by direct download from the device after its return to the monitoring center. The device classes are described in Table 1.

Table 1. Ambulatory Cardiac Rhythm Monitoring Devices

Device Class	Description	Device Examples
Noncontinuous devices with memory (event recorder)	Devices not worn continuously but rather activated by patient and applied to skin in the precordial area when symptoms develop	<ul style="list-style-type: none"> Zio[®]† Event Card (iRhythm Technologies)

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

		<ul style="list-style-type: none"> REKA E100™‡ (REKA Health)
Continuous recording devices with longer recording periods	Devices continuously worn and continuously record via ≥1 cardiac leads and store data longer than traditional Holter (14 days)	<ul style="list-style-type: none"> Zio®‡XT Patch and ZIO ECG Utilization Service (ZEUS) System (iRhythm Technologies)
External memory loop devices (patient- or auto-triggered)	Devices continuously worn and store a single channel of ECG data in a refreshed memory. When the device is activated, the ECG is then recorded from the memory loop for the <i>preceding</i> 30-90 seconds and for next 60 seconds or so. Devices may be activated by a patient when symptoms occur (patient-triggered) or by an automated algorithm when changes suggestive of an arrhythmia are detected (auto-triggered).	<ul style="list-style-type: none"> Patient-triggered: Explorer™‡ Looping Monitor (LifeWatch Services) Auto-triggered: LifeStar AF Express™‡ Auto-Detect Looping Monitor (LifeWatch Services) Auto-triggered or patient-triggered: King of Hearts Express®‡ AF (Card Guard Scientific Survival)
Implantable memory loop devices (patient- or auto-triggered)	Devices similar in design to external memory loop devices but implanted under the skin in the precordial region	<ul style="list-style-type: none"> Auto-triggered or patient-triggered: Reveal®‡ XT ICM (Medtronic) and Confirm Rx Insertable™ Cardiac Monitor (Abbott) Auto-triggered: BioMonitor, Biotronik)

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Mobile cardiac outpatient telemetry	Continuously recording or auto-triggered memory loop devices that transmit data to a central recording station with real-time monitoring and analysis	<ul style="list-style-type: none"> • CardioNet MCOT™‡ (BioTelemetry) • LifeStar Mobile Cardiac Telemetry (LifeWatch Services) • Zio AT(iRhythm)
-------------------------------------	---	--

ECG: electrocardiogram.

There are also devices that combine features of multiple classes. For example, the LifeStar ACT Ex Holter (LifeWatch Services) is a 3-channel Holter monitor, but is converted to a mobile cardiac telemetry system if a diagnosis is inconclusive after 24 to 48 hours of monitoring. The BodyGuardian®‡ Heart Remote Monitoring System (Preventice Services) is an external auto-triggered memory loop device that can be converted to a real-time monitoring system. The eCardio Verité™‡ system (eCardio) can switch between a patient-activated event monitor and a continuous telemetry monitor. The Spiderflash-T (LivaNova) is an example of an external auto-triggered or patient-triggered loop recorder, but like the Zio Patch, can record 2 channels for 14 to 40 days.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Some of the newer devices are described in the Background section for informational purposes. Because there may be many devices within each category, a comprehensive description of individual devices is beyond the scope of this review. U.S. FDA product codes include: DSH, DXH, DQK, DSI, MXD, MHX.

Rationale/Source

Various devices are available for outpatient cardiac rhythm monitoring. These devices differ in the types of monitoring leads used, the duration and continuity of monitoring, the ability to detect arrhythmias without patient intervention, and the mechanism of delivering the information from patient to clinician. These devices may be used to evaluate symptoms suggestive of arrhythmias (eg, syncope, palpitations), and may be used to detect AF in patients who have undergone cardiac ablation of AF or who have a history of cryptogenic stroke.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Ambulatory Event Monitoring

For individuals who have signs and/or symptoms suggestive of arrhythmia(s) who receive patient- or autoactivated external ambulatory event monitoring or continuous ambulatory monitoring storing information for more than 48 hours, the evidence includes 1 randomized controlled trial (RCT) and prospective and retrospective studies reporting on the diagnostic yield. Relevant outcomes are overall survival (OS) and morbid events. The RCT and the observational studies have consistently shown that continuous monitoring with longer recording periods detects more arrhythmias than 24- or 48-hour Holter monitoring. Particularly for patients who, without the more prolonged monitoring, would only undergo shorter term monitoring, the diagnostic yield is likely to identify arrhythmias that may have therapeutic implications. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AF following ablation who receive long-term ambulatory cardiac monitoring, the evidence includes one RCT comparing ambulatory event monitoring with standard care and several observational studies. Relevant outcomes are OS, morbid events, medication use, and treatment-related morbidity. The RCT evaluating a long-term monitoring strategy after catheter ablation for AF reported significantly higher rates of AF detection. The available evidence has suggested that long-term monitoring for AF post ablation is associated with improved outcomes. However, the specific type of monitoring associated with the best outcomes is not established, because different long-term monitoring devices were used across the studies. Trials demonstrating improved outcomes have used event monitors or implantable monitors. In addition, there are individual patient considerations that may make one type of monitor preferable over another. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cryptogenic stroke with a negative standard workup for AF who receive long-term ambulatory cardiac monitoring, the evidence includes systematic reviews of RCTs comparing ambulatory event monitoring with standard care. Relevant outcomes are OS, morbid events, medication use, and treatment-related morbidity. RCTs evaluating a long-term AF monitoring strategy post stroke have reported significantly higher rates of AF detection with longer term ambulatory monitoring. The available evidence has suggested that long-term monitoring for AF after cryptogenic stroke is associated with improved outcomes, but the specific type of monitoring associated with the best outcomes is not established, because different long-term monitoring devices were used across the studies. Trials demonstrating improved outcomes have used

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

event monitors or implantable monitors. In addition, there are individual patient considerations that may make one type of monitor preferable over another. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are asymptomatic with risk factors for AF who receive long-term ambulatory cardiac monitoring, the evidence includes an RCT and observational studies. Relevant outcomes are OS, morbid events, medication use, and treatment-related morbidity. The studies showed use of the ambulatory monitors would result in higher AF detection compared with routine care. However, the RCT followed patients for one year and did not detect a difference in stroke occurrence between the monitored group and the standard of care group. The other studies did not discuss changes in patient management or health outcomes based on monitoring. Studies reporting on improved outcomes with longer follow-up are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Implantable Loop Recording

For individuals who have signs and/or symptoms suggestive of arrhythmia with infrequent symptoms who receive patient- or autoactivated implantable ambulatory event monitoring, the evidence includes RCTs comparing ILRs with shorter term monitoring, usually 24- to 48-hour Holter monitoring, and many observational studies. Relevant outcomes are OS, morbid events, medication use, and treatment-related morbidity. Studies assessing prolonged ILRs in patients have reported high rates of arrhythmia detection compared with shorter external event or Holter monitoring. These studies have supported use of a progression in diagnostics from an external event monitor to ILR when longer monitoring is needed. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Outpatient Cardiac Telemetry

For individuals who have signs and/or symptoms suggestive of arrhythmia who receive outpatient cardiac telemetry, the evidence includes an RCT and nonrandomized studies evaluating rates of arrhythmia detection using outpatient cardiac telemetry. Relevant outcomes are OS and morbid events. The available evidence has suggested that outpatient cardiac telemetry is at least as good at detecting arrhythmias as ambulatory event monitoring. However, studies have not evaluated whether the real-time monitoring feature of outpatient cardiac telemetry leads to reduced cardiac events and mortality. The evidence is insufficient to determine the effects of the technology on health outcomes.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2014 Input

In response to requests, input was received from 3 physician specialty societies and 4 academic medical centers (3 reviews) while this policy was under review in 2014. Input was obtained to provide information on mobile cardiac outpatient telemetry and new devices. There was no consensus whether mobile cardiac outpatient telemetry is medically necessary. While reviewers agreed that mobile cardiac outpatient telemetry is comparable to event monitors for arrhythmia detection, they did not agree on whether the real-time monitoring provides incremental benefit over external event monitors or is associated with improved health outcomes compared with external event monitors. There was consensus on the medical necessity of externally worn event monitors with longer continuous recording periods as an alternative to Holter monitors or event monitors. For implantable memory loop devices that are smaller than older-generation devices, there was consensus that these devices improve the likelihood of obtaining clinically useful information due to improved ease of use, but there was no consensus that such devices improve clinical outcomes and are medically necessary.

2009 Input

In response to requests, input was received from 1 physician specialty society and 4 academic medical centers (5 reviews) while this policy was under review in 2009. There were differences among reviewers on outpatient cardiac telemetry, with some reviewers concluding it had a role in certain subsets of patients (eg, in those with sporadic atrial fibrillation). Other reviewers commented that the value of this technology should be considered in both providing a diagnosis and in making treatment decisions. At times, excluding arrhythmia as a cause of a patient's symptoms is an important finding.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society

The International Society for Holter and Noninvasive Electrocardiology and the Heart Rhythm Society (HRS; 2017) issued a consensus statement on ambulatory electrocardiogram and external monitoring and telemetry. Below are 2 summary tables from the consensus statement, detailing advantages and limitations of ambulatory electrocardiogram techniques (see Table 2) and recommendations for the devices that are relevant to this evidence review (see Table 3).

Table 2. Advantages and Limitations of Ambulatory ECG Techniques, International Society for Holter and Noninvasive Electrocardiology/HRS

ECG Monitoring Technique	Advantages	Limitations
Holter monitoring	<ul style="list-style-type: none"> Records and documents continuous 3- to 32-lead ECG signal simultaneously with biologic signals during normal daily activities Physicians familiar with analysis software and scanning services 	<ul style="list-style-type: none"> Frequent noncompliance with symptom logs and event markers Frequent electrode detachments Signal quality issues due to skin adherence, tangled wires, dermatitis Absence of real-time data analysis Poor patient acceptance of electrodes

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Patch ECG monitors	<ul style="list-style-type: none"> Long-term recording of ≥ 14 days Excellent patient acceptance 	<ul style="list-style-type: none"> Limited ECG from closely spaced electrodes, lacking localization of arrhythmia origin Inconsistent ECG quality due to body type variations
External loop recorders	<ul style="list-style-type: none"> Records only selected ECG segments marked as events either automatically or manually by patient Immediate alarm generation on event detection 	<ul style="list-style-type: none"> Single-lead ECG, lacking localization of arrhythmia origin Cannot continuously document cardiac rhythm Requires patient to wear electrodes continuously
Event recorders	<ul style="list-style-type: none"> Records only selected ECG segments after an event is detected by patient Immediate alarm generation at event detected by patient Well-tolerated by patient 	<ul style="list-style-type: none"> Single-lead ECG, lacking localization of arrhythmia origin Cannot continuously document cardiac rhythm Diagnostic yield dependent on patient ability to recognize correct symptom
Mobile cardiac telemetry	<ul style="list-style-type: none"> Multilead, so higher sensitivity and specificity of arrhythmia detection Streams data continuously; can be programmed to autodetect and autosend events at prescribed time intervals 	<ul style="list-style-type: none"> Long-term patient acceptance is reduced due to requirement of daily electrode changes

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

	<ul style="list-style-type: none"> • Immediate alarm generation on event without patient interaction 	
--	---	--

ECG: electrocardiogram; HRS: Heart Rhythm Society.

Table 3. Select Recommendations for Ambulatory ECG and External Monitoring or Telemetry, International Society for Holter and Noninvasive Electrocardiology/HRS

Recommendation	COR ^a	LOE ^b
Selection of ambulatory ECG		
Holter monitoring when symptomatic events anticipated within 48 hours	I	B-NR
Extended ambulatory ECG (15 to 30 days) when symptomatic events are not daily or are uncertain	I	B-R
Continuous monitoring (1 to 14 days) to quantify arrhythmia burden and patterns	I	B-NR
Specific conditions for use of ambulatory ECG		
Unexplained syncope, when tachycardia suspected	I	B-R
Unexplained palpitation	I	B-R
Detection of atrial fibrillation, triggering arrhythmias, and post conversion pauses	Ia	B-NR
Cryptogenic stroke, to detect undiagnosed atrial fibrillation	I	B-R

ECG: electrocardiogram; COR: class of recommendation; LOE: level of evidence; HRS: Heart Rhythm Society.

^a COR definitions: I: strong recommendation; Ia: benefit probably exceeds risk.

^b LOE definitions: B-NR: moderate level based on well-executed nonrandomized studies; B-R: moderate level based on randomized trials.

American Heart Association, American College of Cardiology, and Heart Rhythm Society

The American College of Cardiology, the American Heart Association, and HRS (2019) updated guidelines initially issued in 2014 on the management of patients with AF. These guidelines

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

recommended the use of Holter or event monitoring if the diagnosis of the type of arrhythmia is in question, or as a means of evaluating rate control.

The same associations (2017) collaborated on guidelines on the evaluation and management of patients with syncope and patients with ventricular arrhythmias. Cardiac monitoring recommendations are summarized below in Tables 4 and 5.

Table 4. Cardiac Monitoring Recommendations, AHA/ACC/HRS

Recommendation	COR^a	LOE^b
Choice of a specific cardiac monitor should be determined on the basis of frequency and nature of syncope events.	I	C-EO
To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, the following external cardiac monitoring approaches can be useful: Holter monitor, transtelephonic monitor, external loop recorder, patch recorder, and mobile cardiac outpatient telemetry.	IIa	B-NR
To evaluate selected ambulatory patients with syncope of suspected arrhythmic etiology, an implantable cardiac monitor can be useful.	IIa	B-R
Ambulatory electrocardiographic monitoring is useful to evaluate whether symptoms including palpitations, presyncope, or syncope, are caused by ventricular arrhythmia	I	B-NR
In patients with cryptogenic stroke (i.e., stroke of unknown cause), in whom external ambulatory monitoring is inconclusive, implantation of a cardiac monitor (loop recorder) is reasonable to optimize detection of silent AF.	IIa	B-R

ACC: American College of Cardiology; AF: atrial fibrillation; AHA: American Heart Association; COR: class of recommendation; HRS: Heart Rhythm Society; LOE: level of evidence.

^a COR definitions: I: strong recommendation; IIa: benefit probably exceeds risk.

^b LOE definitions: B-NR: moderate level based on well-executed nonrandomized studies; B-R: moderate level based on randomized trials; C-EO: consensus of expert opinion based on clinical experience.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

Table 5. Patient Selection Recommendations by Cardiac Rhythm Monitor, AHA/ACC/HRS

Type of Monitor	Patient Selection
Holter monitor	<ul style="list-style-type: none"> Symptoms frequent enough to be detected within 24 to 72 hours
Patient-activated event monitor	<ul style="list-style-type: none"> Frequent spontaneous symptoms likely within 2 to 6 weeks Limited use when syncope associated with sudden incapacitation
External loop recorder (patient or auto-triggered)	<ul style="list-style-type: none"> Frequent spontaneous symptoms likely to occur within 2 to 6 weeks
External patch recorder	<ul style="list-style-type: none"> Alternative to external loop recorder Leadless, so more comfortable, resulting in improved compliance Offers only 1-lead recording
Mobile cardiac outpatient telemetry	<ul style="list-style-type: none"> Spontaneous symptoms related to syncope and rhythm correlation High-risk patients needing real-time monitoring
Implantable cardiac monitor	<ul style="list-style-type: none"> Recurrent, infrequent, unexplained syncope

ACC: American College of Cardiology; AHA: American Heart Association; HRS: Heart Rhythm Society.

Heart Rhythm Society et al

A consensus document on catheter and surgical ablation for AF was published in 2012 by HRS, the European Heart Rhythm Association, and the European Cardiac Arrhythmia Society and updated in

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

2017. This document did not contain formal practice guidelines, but provided general recommendations based on literature review and expert consensus. Use of ambulatory event monitors post ablation was addressed in 2 sections of the document. First, in the section discussing use of anticoagulation following ablation, the following statement was made:

"Patients in whom discontinuation of systematic anticoagulation is being considered based on patient values and preferences should consider undergoing continuous or frequent ECG [electrocardiogram] monitoring to screen for AF recurrence."

In the section on postoperative rhythm monitoring of patients who are post ablation, the following statements were made:

"The success of AF ablation is based in large part on freedom from AF recurrence based on ECG monitoring. Arrhythmia monitoring can be performed with the use of noncontinuous or continuous ECG monitoring tools."

The statement referenced a table of ambulatory cardiac monitoring devices (Holter, patch, external loop, implantable loop, wearable multisensors, Smartphone monitors), describing unique features of each. The table did not evaluate the safety or efficacy of these devices, nor recommend one over another.

European Heart Rhythm Association

The European Heart Rhythm Association (2009) published guidelines on the use of diagnostic implantable and external loop recorders. For the indications that the Association considered established at the time of publication, the guidelines made the following statements about indications for implantable and external recorders (see Table 6).

Table 6. Guidelines on Use of Diagnostic ILRs and ELRs

Recommendation	COR	LOE
<p>"ILR [implantable loop recorder] is indicated:</p> <ul style="list-style-type: none"> "In an early phase of evaluation of patients with recurrent syncope of uncertain origin who have: "absence of high-risk criteria that require immediate hospitalization or intensive evaluation..."; and 	I	A

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

<ul style="list-style-type: none"> "a likely recurrence within battery longevity of the device." 		
"ELRs are indicated in patients with recurrent palpitations, undocumented by conventional ECG techniques, who have: inter-symptom interval <4 weeks and absence of high-risk criteria...which require immediate hospitalization or intensive evaluation."	I	B
"ILR may be indicated to assess the contribution of bradycardia before embarking on cardiac pacing in patients with suspected or certain neurally mediated syncope presenting with frequent or traumatic syncopal episodes."	IIa	B
"ILRs may be indicated in selected cases with severe infrequent symptoms when ELRs and other ECG monitoring systems fail to document the underlying cause."	IIa	B
<p>"ELRs [external loop recorder] may be indicated in patients with recurrent (pre)syncopes who have:</p> <ul style="list-style-type: none"> "inter-symptom interval of ≤ 4 weeks, and "suspicion of arrhythmic origin and "absence of high-risk criteria that require immediate hospitalization or intensive evaluation...." 	IIa	B

COR: class of recommendations; ECG: electrocardiogram; ELR: external loop recorder; ILR: implantable loop recorder; LOE: level of evidence.

American Academy of Neurology

The American Academy of Neurology updated its guidelines on the prevention of stroke in patients with nonvalvular AF (NVAF). These guidelines made the following recommendations on the identification of patients with occult NVAF:

A1. "Clinicians might obtain outpatient cardiac rhythm studies in patients with cryptogenic stroke without known NVAF, to identify patients with occult NVAF (Level C).

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

A2. Clinicians might obtain cardiac rhythm studies for prolonged periods (e.g., for 1 or more weeks) instead of shorter periods (e.g., 24 hours) in patients with cryptogenic stroke without known NVAf, to increase the yield of identification of patients with occult NVAf (Level C)."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services (2004) implemented a national coverage determination for electrocardiographic services. This national coverage determination includes descriptions of the Holter monitor and event recorders (both external loop recorders and implantable loop recorders). Ambulatory cardiac monitors are covered when there is documentation of medical necessity. Indications for use include detection of symptomatic transient arrhythmias and determination of arrhythmic drug therapy (to either initiate, revise, or discontinue the therapy).

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 7.

Table 7. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT03072693	Daily Ambulatory Remote Monitoring System vs Conventional Therapy for the Post-Discharge Management of Acute Decompensated Heart Failure	876	Jul 2022
NCT02684825	Detection of Silent Atrial Fibrillation after Ischemic Stroke (SAFFO)	424	Jun 2021
NCT03221777	Atrial Fibrillation Occurring Transiently with Stress (AFOTS): Understanding the Risks of Recurrent AF. Study in Non-cardiac Surgery and in Medical Illness Patients	276	Oct 2021

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

NCT04126486 ^a	GUARD-AF: reducing Stroke by Screening for Undiagnosed atrial Fibrillation in Elderly individuals	52,000	Jul 2021
NCT02786940	Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients after Discharge (REMOSYNC)	99	March 2023
NCT03541616	Prevalence of Subclinical Atrial Fibrillation in High Risk Heart Failure Patients and Its Temporal Relationship With Hospital Readmission for Heart Failure	240	Apr 2022
<i>Unpublished</i>			
NCT02428140	Post-Embolic Rhythm Detection with Implantable Versus External Monitoring (PERDIEM)	300	Dec 2019
NCT02793895	Detection of Atrial Fibrillation After Cardiac Surgery (SEARCH-AF)	396	Dec 2020

^a Denotes industry involvement

NCT: national clinical trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry”, 2.02.08, June 2021.
2. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). *Eur Heart J*. Nov 2009; 30(21): 2631-71. PMID 19713422
3. National Institute for Health and Care Excellence (NICE). Transient loss of consciousness ('blackouts') in over 16s [CG109]. 2014; <https://www.nice.org.uk/guidance/cg109>.
4. Raviele A, Giada F, Bergfeldt L, et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. *Europace*. Jul 2011; 13(7): 920-34. PMID 21697315
5. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

- Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. Dec 02 2014; 130(23): 2071-104. PMID 24682348
6. Mittal S, Movsowitz C, Steinberg JS. Ambulatory external electrocardiographic monitoring: focus on atrial fibrillation. *J Am Coll Cardiol*. Oct 18 2011; 58(17): 1741-9. PMID 21996384
 7. Christensen LM, Krieger DW, Hojberg S, et al. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. *Eur J Neurol*. Jun 2014; 21(6): 884-9. PMID 24628954
 8. Hoefman E, Bindels PJ, van Weert HC. Efficacy of diagnostic tools for detecting cardiac arrhythmias: systematic literature search. *Neth Heart J*. Nov 2010; 18(11): 543-51. PMID 21113379
 9. Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. *JAMA*. Jul 10 2018; 320(2): 146-155. PMID 29998336
 10. Farris GR, Smith BG, Oates ET, et al. New atrial fibrillation diagnosed by 30-day rhythm monitoring. *Am Heart J*. Mar 2019; 209: 29-35. PMID 30639611
 11. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. *Am J Cardiol*. Aug 15 2013; 112(4): 520-4. PMID 23672988
 12. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. *Am J Med*. Jan 2014; 127(1): 95.e11-7. PMID 24384108
 13. Solomon MD, Yang J, Sung SH, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord*. Feb 17 2016; 16: 35. PMID 26883019
 14. Wineinger NE, Barrett PM, Zhang Y, et al. Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals. *Heart Rhythm*. Jan 2019; 16(1): 26-30. PMID 30118885
 15. Go AS, Reynolds K, Yang J, et al. Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP-RHYTHM Study. *JAMA Cardiol*. Jul 01 2018; 3(7): 601-608. PMID 29799942
 16. Bolourchi M, Batra AS. Diagnostic yield of patch ambulatory electrocardiogram monitoring in children (from a national registry). *Am J Cardiol*. Mar 01 2015; 115(5): 630-4. PMID 25591894
 17. Eisenberg EE, Carlson SK, Doshi RH, et al. Chronic ambulatory monitoring: results of a large single-center experience. *J Innovations Cardiac Rhythm Manage*. Nov 2014;5:1818-1823.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

18. Schreiber D, Sattar A, Drigalla D, et al. Ambulatory cardiac monitoring for discharged emergency department patients with possible cardiac arrhythmias. *West J Emerg Med.* Mar 2014; 15(2): 194-8. PMID 24672611
19. Mullis AH, Ayoub K, Shah J, et al. Fluctuations in premature ventricular contraction burden can affect medical assessment and management. *Heart Rhythm.* Oct 2019; 16(10): 1570-1574. PMID 31004780
20. Reed MJ, Grubb NR, Lang CC, et al. Diagnostic yield of an ambulatory patch monitor in patients with unexplained syncope after initial evaluation in the emergency department: the PATCH-ED study. *Emerg Med J.* Aug 2018; 35(8): 477-485. PMID 29921622
21. Eysenck W, Freemantle N, Sulke N. A randomized trial evaluating the accuracy of AF detection by four external ambulatory ECG monitors compared to permanent pacemaker AF detection. *J Interv Card Electrophysiol.* Apr 2020; 57(3): 361-369. PMID 30741360
22. Kabali C, Xie X, Higgins C. Long-Term Continuous Ambulatory ECG Monitors and External Cardiac Loop Recorders for Cardiac Arrhythmia: A Health Technology Assessment. *Ont Health Technol Assess Ser.* 2017; 17(1): 1-56. PMID 28194254
23. Balmelli N, Naegeli B, Bertel O. Diagnostic yield of automatic and patient-triggered ambulatory cardiac event recording in the evaluation of patients with palpitations, dizziness, or syncope. *Clin Cardiol.* Apr 2003; 26(4): 173-6. PMID 12708623
24. Ermis C, Zhu AX, Pham S, et al. Comparison of automatic and patient-activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope. *Am J Cardiol.* Oct 01 2003; 92(7): 815-9. PMID 14516882
25. Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. *Am J Cardiol.* May 01 2005; 95(9): 1055-9. PMID 15842970
26. Dages N, Kottkamp H, Piorowski C, et al. :Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. *Int J Cardiol.* Mar 18 2010; 139(3): 305-6. PMID 18990460
27. Pokushalov E, Romanov A, Corbucci G, et al. Ablation of paroxysmal and persistent atrial fibrillation: 1-year follow-up through continuous subcutaneous monitoring. *J Cardiovasc Electrophysiol.* Apr 2011; 22(4): 369-75. PMID 20958836
28. Chao TF, Lin YJ, Tsao HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. *J Am Coll Cardiol.* Nov 29 2011; 58(23): 2380-5. PMID 22115643

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

29. Kapa S, Epstein AE, Callans DJ, et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. *J Cardiovasc Electrophysiol.* Aug 2013; 24(8): 875-81. PMID 23577826
30. Verma A, Champagne J, Sapp J, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. *JAMA Intern Med.* Jan 28 2013; 173(2): 149-56. PMID 23266597
31. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. *J Am Coll Cardiol.* Feb 23 2010; 55(8): 735-43. PMID 20170810
32. Gumbinger C, Krumdorf U, Veltkamp R, et al. Continuous monitoring versus HOLTER ECG for detection of atrial fibrillation in patients with stroke. *Eur J Neurol.* Feb 2012; 19(2): 253-7. PMID 21895885
33. Lazzaro MA, Krishnan K, Prabhakaran S. Detection of atrial fibrillation with concurrent holter monitoring and continuous cardiac telemetry following ischemic stroke and transient ischemic attack. *J Stroke Cerebrovasc Dis.* Feb 2012; 21(2): 89-93. PMID 20656504
34. Cotter PE, Martin PJ, Ring L, et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. *Neurology.* Apr 23 2013; 80(17): 1546-50. PMID 23535493
35. Miller DJ, Khan MA, Schultz LR, et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. *J Neurol Sci.* Jan 15 2013; 324(1-2): 57-61. PMID 23102659
36. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol.* Apr 2015; 14(4): 377-87. PMID 25748102
37. Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke.* Feb 2014; 45(2): 520-6. PMID 24385275
38. Kamel H, Navi BB, Eljovich L, et al. Pilot randomized trial of outpatient cardiac monitoring after cryptogenic stroke. *Stroke.* Feb 2013; 44(2): 528-30. PMID 23192756
39. Higgins P, MacFarlane PW, Dawson J, et al. Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. *Stroke.* Sep 2013; 44(9): 2525-31. PMID 23899913
40. Sinha AM, Diener HC, Morillo CA, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. *Am Heart J.* Jul 2010; 160(1): 36-41.e1. PMID 20598970

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

41. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med.* Jun 26 2014; 370(26): 2478-86. PMID 24963567
42. Brachmann J, Morillo CA, Sanna T, et al. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. *Circ Arrhythm Electrophysiol.* Jan 2016; 9(1): e003333. PMID 26763225
43. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med.* Jun 26 2014; 370(26): 2467-77. PMID 24963566
44. Kaura A, Sztrihá L, Chan FK, et al. Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial. *Eur J Med Res.* Jul 26 2019; 24(1): 25. PMID 31349792
45. Ritter MA, Kochhauser S, Duning T, et al. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. *Stroke.* May 2013; 44(5): 1449-52. PMID 23449264
46. Etgen T, Hochreiter M, Mundel M, et al. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. *Stroke.* Jul 2013; 44(7): 2007-9. PMID 23674523
47. Tung CE, Su D, Turakhia MP, et al. Diagnostic Yield of Extended Cardiac Patch Monitoring in Patients with Stroke or TIA. *Front Neurol.* 2014; 5: 266. PMID 25628595
48. Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. *Pacing Clin Electrophysiol.* Mar 2013; 36(3): 328-33. PMID 23240827
49. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. *J Interv Card Electrophysiol.* Jun 2000; 4(2): 369-82. PMID 10936003
50. Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. *J Am Coll Cardiol.* Jan 07 2004; 43(1): 47-52. PMID 14715182
51. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. *Circulation.* Jan 1994; 89(1): 224-7. PMID 8281651
52. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. *Stroke Prevention in Atrial Fibrillation Investigators.* *J Am Coll Cardiol.* Jan 2000; 35(1): 183-7. PMID 10636278

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

53. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. *J Am Coll Cardiol.* Nov 27 2007; 50(22): 2156-61. PMID 18036454
54. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. *Eur Heart J.* May 21 2016; 37(20): 1591-602. PMID 26888184
55. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ.* Aug 25 2007; 335(7616): 383. PMID 17673732
56. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol.* May 2015; 38(5): 285-92. PMID 25873476
57. Heckbert SR, Austin TR, Jensen PN, et al. Yield and consistency of arrhythmia detection with patch electrocardiographic monitoring: The Multi-Ethnic Study of Atherosclerosis. *J Electrocardiol.* Nov 2018; 51(6): 997-1002. PMID 30497763
58. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. *Circulation.* Nov 07 2017; 136(19): 1784-1794. PMID 28851729
59. Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. *JAMA Cardiol.* May 01 2021; 6(5): 558-567. PMID 33625468
60. Solbiati M, Casazza G, Dipaola F, et al. The diagnostic yield of implantable loop recorders in unexplained syncope: A systematic review and meta-analysis. *Int J Cardiol.* Mar 15 2017; 231: 170-176. PMID 28052814
61. Burkowitz J, Merzenich C, Grassme K, et al. Insertable cardiac monitors in the diagnosis of syncope and the detection of atrial fibrillation: A systematic review and meta-analysis. *Eur J Prev Cardiol.* Aug 2016; 23(12): 1261-72. PMID 26864396
62. Da Costa A, Defaye P, Romeyer-Bouchard C, et al. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative workup: a randomized multicentre prospective study. *Arch Cardiovasc Dis.* Mar 2013; 106(3): 146-54. PMID 23582676
63. Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. *Eur Heart J.* Jul 2004; 25(14): 1257-63. PMID 15246645

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

64. Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. *Circulation*. Jul 03 2001; 104(1): 46-51. PMID 11435336
65. Afzal MR, Gunda S, Waheed S, et al. Role of Outpatient Cardiac Rhythm Monitoring in Cryptogenic Stroke: A Systematic Review and Meta-Analysis. *Pacing Clin Electrophysiol*. Oct 2015; 38(10): 1236-45. PMID 26172621
66. Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). *Arch Cardiovasc Dis*. Oct 2014; 107(10): 546-52. PMID 25241220
67. Giada F, Gulizia M, Francese M, et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. *J Am Coll Cardiol*. May 15 2007; 49(19): 1951-6. PMID 17498580
68. Magnusson PM, Olszowka M, Wallhagen M, et al. Outcome of implantable loop recorder evaluation. *Cardiol J*. 2018; 25(3): 363-370. PMID 28840588
69. Maines M, Zorzi A, Tomasi G, et al. Clinical impact, safety, and accuracy of the remotely monitored implantable loop recorder Medtronic Reveal LINQ™. *Europace*. Jun 01 2018; 20(6): 1050-1057. PMID 29016753
70. Ciconte G, Saviano M, Giannelli L, et al. Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detect study. *Europace*. Jul 01 2017; 19(7): 1101-1108. PMID 27702865
71. Bhangu J, McMahon CG, Hall P, et al. Long-term cardiac monitoring in older adults with unexplained falls and syncope. *Heart*. May 2016; 102(9): 681-6. PMID 26822427
72. Nolker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. *J Cardiovasc Electrophysiol*. Dec 2016; 27(12): 1403-1410. PMID 27565119
73. Sanders P, Purerfellner H, Pokushalov E, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. *Heart Rhythm*. Jul 2016; 13(7): 1425-30. PMID 26961298
74. Ziegler PD, Rogers JD, Ferreira SW, et al. Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. *Cerebrovasc Dis*. 2015; 40(3-4): 175-81. PMID 26314298
75. Edvardsson N, Garutti C, Rieger G, et al. Unexplained syncope: implications of age and gender on patient characteristics and evaluation, the diagnostic yield of an implantable loop recorder, and the subsequent treatment. *Clin Cardiol*. Oct 2014; 37(10): 618-25. PMID 24890550

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

76. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. *Circ Arrhythm Electrophysiol.* Apr 2010; 3(2): 141-7. PMID 20160169
77. Hanke T, Charitos EI, Stierle U, et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. *Circulation.* Sep 15 2009; 120(11 Suppl): S177-84. PMID 19752365
78. Mittal S, Sanders P, Pokushalov E, et al. Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials. *Pacing Clin Electrophysiol.* Dec 2015; 38(12): 1464-9. PMID 26412309
79. Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. *J Cardiovasc Electrophysiol.* Mar 2007; 18(3): 241-7. PMID 17318994
80. Derkac WM, Finkelmeier JR, Horgan DJ, et al. Diagnostic yield of asymptomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger looping event cardiac monitors. *J Cardiovasc Electrophysiol.* Dec 2017; 28(12): 1475-1478. PMID 28940881
81. Kadish AH, Reiffel JA, Clauser J, et al. Frequency of serious arrhythmias detected with ambulatory cardiac telemetry. *Am J Cardiol.* May 01 2010; 105(9): 1313-6. PMID 20403485
82. Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. *Am J Cardiol.* Apr 01 2005; 95(7): 878-81. PMID 15781022
83. Olson JA, Fouts AM, Padanilam BJ, et al. Utility of mobile cardiac outpatient telemetry for the diagnosis of palpitations, presyncope, syncope, and the assessment of therapy efficacy. *J Cardiovasc Electrophysiol.* May 2007; 18(5): 473-7. PMID 17343724
84. Saarel EV, Doratotaj S, Sterba R. Initial experience with novel mobile cardiac outpatient telemetry for children and adolescents with suspected arrhythmia. *Congenit Heart Dis.* Jan-Feb 2008; 3(1): 33-8. PMID 18373747
85. Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. *Neurology.* Nov 18 2008; 71(21): 1696-701. PMID 18815386
86. Favilla CG, Ingala E, Jara J, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. *Stroke.* May 2015; 46(5): 1210-5. PMID 25851771

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

87. Kalani R, Bernstein R, Passman R, et al. Low Yield of Mobile Cardiac Outpatient Telemetry after Cryptogenic Stroke in Patients with Extensive Cardiac Imaging. *J Stroke Cerebrovasc Dis.* Sep 2015; 24(9): 2069-73. PMID 26139455
88. Narasimha D, Hanna N, Beck H, et al. Validation of a smartphone-based event recorder for arrhythmia detection. *Pacing Clin Electrophysiol.* May 2018; 41(5): 487-494. PMID 29493801
89. Dorr M, Nohturfft V, Brasier N, et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. *JACC Clin Electrophysiol.* Feb 2019; 5(2): 199-208. PMID 30784691
90. Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart Rhythm.* Jul 2017; 14(7): e55-e96. PMID 28495301
91. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm.* Aug 2019; 16(8): e66-e93. PMID 30703530
92. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* Aug 01 2017; 70(5): 620-663. PMID 28286222
93. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm.* Oct 2018; 15(10): e190-e252. PMID 29097320
94. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *J Interv Card Electrophysiol.* Mar 2012; 33(2): 171-257. PMID 22382715
95. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *J Arrhythm.* Oct 2017; 33(5): 369-409. PMID 29021841
96. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. *Europace.* May 2009; 11(5): 671-87. PMID 19401342

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

- 97. Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. Feb 25 2014; 82(8): 716-24. PMID 24566225
- 98. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Electrocardiographic Services (20.15). 2004; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?MCDId=16&ExpandComments=n&McdName=Thomson+Micromedex+DrugDex+%C2%AE+Compendium+Revision+Request+-+CAG-00391&NCDId=179>.

Policy History

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

- 08/01/2019 Medical Policy Committee review
 - 08/21/2019 Medical Policy Implementation Committee approval. New policy.
 - 08/06/2020 Medical Policy Committee review
 - 08/12/2020 Medical Policy Implementation Committee approval. Clarified criteria.
 - 08/05/2021 Medical Policy Committee review
 - 08/11/2021 Medical Policy Implementation Committee approval. No change to coverage.
- Next Scheduled Review Date: 08/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units,

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	33285, 93228, 93229
HCPCS	C1764, E0616
ICD-10 Diagnosis	I44.0-I44.7, I45.0-I45.9, I47.0-I47.9, I48.0-I48.1, I48.11-I48.21, I49.01-I49.9, I63.9, R00.2, R42, R55

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Policy # 00682

Original Effective Date: 11/01/2019

Current Effective Date: 09/13/2021

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.